T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Roivant Sciences
ROIV
$26.3B
| $116M | 0.01% |
5,335,125
+2,414,629
| +83% | +$47.6M |
|
602
Rocket Lab Corp
RKLB
$51.9B
| $115M | 0.01% |
1,648,489
+12,383
| +0.8% | +$710K |
|
603
Galicia Financial Group
GGAL
$7.09B
| $114M | 0.01% |
2,116,925
+380,643
| +22% | +$17.8M |
|
604
Mirum Pharmaceuticals
MIRM
$6.07B
| $112M | 0.01% |
1,420,375
+137,087
| +11% | +$9.84M |
|
605
Liberty Live Group Series C
LLYVK
$9.88B
| $112M | 0.01% |
1,341,554
-146,829
| -10% | -$12.6M |
|
606
Bruker
BRKR
$8.88B
| $111M | 0.01% |
2,366,520
+2,289,269
| +2,963% | +$96.7M |
|
607
Viasat
VSAT
$11.8B
| $111M | 0.01% |
3,222,981
+3,112,670
| +2,822% | +$110M |
|
608
Roku
ROKU
$22.7B
| $111M | 0.01% |
1,020,917
+561,666
| +122% | +$57M |
|
609
Mueller Industries
MLI
$14.8B
| $110M | 0.01% |
1,921,578
+287,184
| +18% | +$15.4M |
|
610
HEICO Corp
HEI
$51.5B
| $109M | 0.01% |
337,064
+29,133
| +9% | +$9.21M |
|
611
T. Rowe Price Growth Stock ETF
TGRW
$1.04B
| $109M | 0.01% |
2,370,001
+275,000
| +13% | +$12.6M |
|
612
Shoals Technologies Group
SHLS
$1.4B
| $108M | 0.01% |
12,753,784
+7,685,515
| +152% | +$69M |
|
613
Alignment Healthcare
ALHC
$2.81B
| $108M | 0.01% |
5,466,117
-107,082
| -2% | -$1.92M |
|
614
Curtiss-Wright
CW
$25.6B
| $107M | 0.01% |
194,868
-5,624
| -3% | -$3.14M |
|
615
Onto Innovation
ONTO
$20.8B
| $107M | 0.01% |
680,266
-95,797
| -12% | -$13.6M |
|
616
Viridian Therapeutics
VRDN
$2.53B
| $107M | 0.01% |
3,439,414
+1,021,310
| +42% | +$28M |
|
617
Sterling Infrastructure
STRL
$16.9B
| $107M | 0.01% |
349,481
-351,777
| -50% | -$121M |
|
618
Lemonade
LMND
$4.02B
| $106M | 0.01% |
1,484,175
+965,321
| +186% | +$64.8M |
|
619
Cushman & Wakefield Ltd
CWK
$3.29B
| $106M | 0.01% |
6,519,263
+1,233,055
| +23% | +$19.5M |
|
|
ACLX
620
DELISTED
Arcellx
ACLX
| $105M | 0.01% |
1,610,801
+346,750
| +27% | +$27.7M |
|
621
Warner Bros
WBD
$69.8B
| $104M | 0.01% |
3,622,628
-9,364
| -0.3% | -$219K |
|
622
American Water Works
AWK
$27.2B
| $104M | 0.01% |
794,606
-2,817,065
| -78% | -$376M |
|
623
LPL Financial
LPLA
$29.3B
| $103M | 0.01% |
289,691
+18,678
| +7% | +$6.61M |
|
624
BWX Technologies
BWXT
$15.5B
| $103M | 0.01% |
598,295
-96,944
| -14% | -$18.2M |
|
625
FTAI Aviation
FTAI
$22.6B
| $103M | 0.01% |
523,692
+232,852
| +80% | +$39.7M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.